Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

Abstract • About • The 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Diabetes

  Free Subscription


10.11.2025

5 Am J Clin Nutr
1 Am J Nephrol
1 Angiology
2 Ann Intern Med
3 Biochem Biophys Res Commun
1 BMC Ophthalmol
2 Diabet Med
2 Diabetes
4 Diabetes Care
29 Diabetes Obes Metab
8 Diabetologia
4 Invest Ophthalmol Vis Sci
1 J Biol Chem
2 J Clin Endocrinol Metab
4 J Clin Invest
5 J Diabetes Complications
3 J Hypertens
1 JAMA
1 Metabolism
1 Ophthalmol Retina
3 Pediatr Diabetes
9 PLoS One
1 Transplant Proc
1 WMJ


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Nutr

  1. POTTER AW, Friedl KE
    Cross-sectional analysis of visceral adipose tissue associations with obesity-related disease.
    Am J Clin Nutr. 2025;122:1489-1497.
    PubMed         Abstract available

  2. SHI L, Zheng R, Brunius C, Byberg L, et al
    Novel protein targets for type 2 diabetes prevention and their mediating role in the diet-disease relationship: evidence from 2 population-based cohorts and a Mendelian randomization analysis.
    Am J Clin Nutr. 2025;122:1400-1412.
    PubMed         Abstract available

  3. ANJOM-SHOAE J, Wu T, Horowitz M
    Proteins and the crossroads of diet and type 2 diabetes.
    Am J Clin Nutr. 2025;122:1143-1144.
    PubMed        

  4. WANG Y, Xu Q, Lu S, Wu X, et al
    The effect of muscle quality index on risk of adverse health outcomes: a prospective cohort study of 355,209 adults.
    Am J Clin Nutr. 2025;122:1452-1460.
    PubMed         Abstract available

  5. BAEK O, Klabunde B, Wang T, Bonnelykke K, et al
    A scoping review on the possible immunometabolic properties of the furan fatty acid metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.
    Am J Clin Nutr. 2025;122:1155-1160.
    PubMed         Abstract available


    Am J Nephrol

  6. MC CAUSLAND FR, Claggett BL, Jarolim P, McGrath MM, et al
    Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia.
    Am J Nephrol. 2025 Nov 3:1-19. doi: 10.1159/000549255.
    PubMed         Abstract available


    Angiology

  7. ZHU Y, Wang YS, Zhang GP, Ma F, et al
    Association of Liver Fat Content With Carotid Endothelial Function in Patients With Newly Diagnosed Type 2 Diabetes Mellitus and Pre-Diabetes Mellitus.
    Angiology. 2025 Nov 6:33197251384344. doi: 10.1177/00033197251384344.
    PubMed         Abstract available


    Ann Intern Med

  8. LESSER LI
    In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.
    Ann Intern Med. 2025 Nov 4. doi: 10.7326/ANNALS-25-04321.
    PubMed         Abstract available

  9. CRISAFULLI S, Alkabbani W, Paik JM, Bykov K, et al
    Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.
    Ann Intern Med. 2025 Nov 4. doi: 10.7326/ANNALS-25-01724.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  10. KAUR M, Dahiya N, Singh V
    Ornithine decarboxylase 1 modulation regulates plasma membrane integrity and associated gene networks under glucotoxicity and lipotoxicity stress: An in vitro study.
    Biochem Biophys Res Commun. 2025;788:152807.
    PubMed         Abstract available

  11. REIS-BARBOSA PH, Cardoso LEM, Mandarim-de-Lacerda CA
    Tirzepatide improves extracellular matrix integrity and vascularization in pancreatic islets of a mouse model of obesity, diabetes, and menopause.
    Biochem Biophys Res Commun. 2025;790:152913.
    PubMed         Abstract available

  12. SHI Q, Sun W, Zhou Z, Zhao J, et al
    PKA-mediated Drp1 Ser637 phosphorylation modulates mitochondrial function in the placenta of gestational diabetes mellitus.
    Biochem Biophys Res Commun. 2025;790:152919.
    PubMed         Abstract available


    BMC Ophthalmol

  13. WANG S, Meng L, Yang H
    The effects of L-tartaric acid on diabetic cataracts through modulation of oxidative stress and inflammation in diabetic rats.
    BMC Ophthalmol. 2025;25:615.
    PubMed         Abstract available


    Diabet Med

  14. REED-BERENDT R, Bell J, Hatherall L, Hayes H, et al
    Towards better Diabetes Data Rights: Data protection, data 'ownership', and developing a patient charter.
    Diabet Med. 2025 Nov 6:e70160. doi: 10.1111/dme.70160.
    PubMed         Abstract available

  15. PEMBERTON JS, Russon CL, Pulsford RM, Metcalf BS, et al
    Physical activity (20 min) is a powerful adjunct to insulin for correcting hyperglycaemia in Type 1 diabetes: A paradigm shift.
    Diabet Med. 2025 Nov 5:e70163. doi: 10.1111/dme.70163.
    PubMed        


    Diabetes

  16. OROZCO S, Aljobaily N, Reynolds HM, Oceguera GA, et al
    Flt3L-Derived Antigen-Presenting Cell Transfer in Neonatal NOD Mice Reduces the Incidence of Type 1 Diabetes.
    Diabetes. 2025 Nov 6:db250055. doi: 10.2337/db25-0055.
    PubMed         Abstract available

  17. AGARWAL M, Chandrakumar S, Santiago Tierno I, Lessieur EM, et al
    Lysyl Oxidase Promotes Actin-Dependent Neutrophil Activation and Cytotoxicity Toward Retinal Endothelial Cells in Diabetes.
    Diabetes. 2025 Nov 4:db250541. doi: 10.2337/db25-0541.
    PubMed         Abstract available


    Diabetes Care

  18. SAJJADI SF, Sacre JW, Salim A, Oldenburg B, et al
    Association of the Age at Type 2 Diabetes Onset With Diabetes Progression.
    Diabetes Care. 2025 Nov 7:dc251811. doi: 10.2337/dc25-1811.
    PubMed         Abstract available

  19. LIN YK, Tang H, Ye W, Ratzki-Leewing A, et al
    Hypoglycemia Beliefs, Impaired Hypoglycemia Awareness, and Severe Hypoglycemia in Insulin-Treated Type 2 Diabetes: Insights From CGM Users.
    Diabetes Care. 2025 Nov 6:dc251778. doi: 10.2337/dc25-1778.
    PubMed        

  20. MATHIEU C, Sims EK, Chatenoud L, James EA, et al
    Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab.
    Diabetes Care. 2025 Nov 6:dci250066. doi: 10.2337/dci25-0066.
    PubMed         Abstract available

  21. RO AE, Morales C, Jiang L, Choi JM, et al
    Changes in Type 2 Diabetes Medications Among Primary Care Patients After California's 2022 Medicaid Expansion.
    Diabetes Care. 2025 Nov 5:dc250787. doi: 10.2337/dc25-0787.
    PubMed         Abstract available


    Diabetes Obes Metab

  22. WITTHAUER L, Mendez C, Garcia-Tirado J, Eichenlaub M, et al
    Discrepancies between current displayed and auto-logged glucose values in FreeStyle Libre 3: Implications for clinical interpretation.
    Diabetes Obes Metab. 2025;27:7367-7373.
    PubMed         Abstract available

  23. BELL DSH, Jerkins TW
    Diabetic distal symmetric polyneuropathy: More than just "tingling in the feet".
    Diabetes Obes Metab. 2025 Nov 6. doi: 10.1111/dom.70235.
    PubMed         Abstract available

  24. ASTBURY NM, Ripullone K, Ramakrishnan R, Woodwood M, et al
    Associations between gestational diabetes and cardiovascular disease largely operate independently of postpartum causal pathways: A population-based cohort study in England.
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70210.
    PubMed         Abstract available

  25. DEUSCH K, Deboek A, Sina C, Capo-Velez C, et al
    Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials.
    Diabetes Obes Metab. 2025;27:7344-7354.
    PubMed         Abstract available

  26. FENG W, Zhu S, Kong L, Zhang W, et al
    Deletion of RalGAPbeta protects pancreatic beta cells and improves glycemic control.
    Diabetes Obes Metab. 2025;27:7323-7343.
    PubMed         Abstract available

  27. KIM J, Raggi P, Carreau AM, Wharton S, et al
    A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.
    Diabetes Obes Metab. 2025;27:6831-6846.
    PubMed         Abstract available

  28. SIDDIQUI HF, Ali D, Sajid M, Qureshi S, et al
    Sex differences in the efficacy of GLP-1 receptor agonists: A systematic review and meta-analysis of cardiovascular and renal outcome trials.
    Diabetes Obes Metab. 2025;27:6847-6856.
    PubMed         Abstract available

  29. XIAO YJ, Yu S, Zhang YL, Chen J, et al
    Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025;27:7062-7074.
    PubMed         Abstract available

  30. LAN Y, Wu D, Feng B, Ding X, et al
    Acute inflammation amplifies the diabetogenic effect of excess adiposity: Evidence from a real-life, prospective cohort.
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70274.
    PubMed         Abstract available

  31. HONG S, Kim WJ, Kim S, Park JH, et al
    Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study).
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70258.
    PubMed         Abstract available

  32. SHEN J, Zeng T, Li X, Zheng C, et al
    Safety and efficacy of hybrid closed-loop insulin pump therapy in adolescents and adults with type 1 diabetes in China.
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70227.
    PubMed         Abstract available

  33. DONNELLY LA, Singh K, McCrimmon RJ, Pearson ER, et al
    One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.
    Diabetes Obes Metab. 2025 Nov 4. doi: 10.1111/dom.70269.
    PubMed         Abstract available

  34. KETEMA DB, Joshi R, Hailu W, Gallagher M, et al
    Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70268.
    PubMed         Abstract available

  35. RATZKI-LEEWING A, Black JE, Bhatti J, Ryan BL, et al
    Real-world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes (iNPHORM, United States).
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70252.
    PubMed         Abstract available

  36. LIU X, Chen X, Yang W, Ding G, et al
    Cardiorespiratory fitness and type 2 diabetes risk: A prospective cohort study with mediation analysis of biological aging in the UK Biobank.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70261.
    PubMed         Abstract available

  37. AIMELET V, Holst JJ
    Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70229.
    PubMed         Abstract available

  38. LANDGRAF W, Owens DR, Frier BM, Bolli GB, et al
    Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70231.
    PubMed         Abstract available

  39. SCILLETTA S, Welsh P, Di Pino A, Sattar N, et al
    Progressive increases in adiposity and ectopic fat surrogates across glycaemic states highlight weight reduction as a key target for type 2 diabetes prevention, especially in younger people.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70248.
    PubMed         Abstract available

  40. MAQSOOD S, Sarwar MA, Belousoviene E, Maskeliunas R, et al
    GlucoNet-MM: A multimodal attention-based multi-task learning framework with decision transformer for personalised and explainable blood glucose forecasting.
    Diabetes Obes Metab. 2025;27:7416-7430.
    PubMed         Abstract available

  41. JIA W, Jiang F, Xu Y, Li Y, et al
    Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.
    Diabetes Obes Metab. 2025;27:7123-7132.
    PubMed         Abstract available

  42. YANG X, Tang W, Chan H, Wang M, et al
    Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control.
    Diabetes Obes Metab. 2025;27:7395-7407.
    PubMed         Abstract available

  43. WRUBLEWSKY S, Bickelmann C, Messmer LS, Wilden C, et al
    Boosting the engraftment of subcutaneously transplanted pancreatic islets by nanofat.
    Diabetes Obes Metab. 2025;27:7258-7274.
    PubMed         Abstract available

  44. NEFF GW
    Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.
    Diabetes Obes Metab. 2025;27:6869-6883.
    PubMed         Abstract available

  45. CHOUDHARY P, Kao K, Quadri F, Balogh E, et al
    Contributions of intermittently scanned continuous glucose monitoring frequency and bolus insulin dosing on time in range: Analysis of data from CGM and connected insulin pens.
    Diabetes Obes Metab. 2025;27:7570-7577.
    PubMed         Abstract available

  46. CARTER P, Simo R, Lovestam-Adrian M, Pearce I, et al
    Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus.
    Diabetes Obes Metab. 2025;27:7535-7543.
    PubMed         Abstract available

  47. MANTOVANI A, Lombardi R, Dalbeni A, Morandin R, et al
    Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study.
    Diabetes Obes Metab. 2025 Nov 2. doi: 10.1111/dom.70245.
    PubMed         Abstract available

  48. ELKIND-HIRSCH K, Armatta M, Griffen C, Welsh JB, et al
    Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes-The Steady Sugar trial.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70254.
    PubMed         Abstract available

  49. PATHAK A, Hardin MB, Girard M, Davies MJ, et al
    Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70266.
    PubMed        

  50. HENNEY AE, Heague M, Riley DR, Hydes TJ, et al
    Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70267.
    PubMed         Abstract available


    Diabetologia

  51. HO QWC, Miller JA, Gunaseelan D, Chelliah R, et al
    I-BET151 modulates glucokinase gene expression and beta cell function in part through changes in FOXO1 expression.
    Diabetologia. 2025;68:2767-2780.
    PubMed         Abstract available

  52. LAMARCHE LB, Koch C, Khalid S, Khan MZ, et al
    Complete loss of SLC30A8 in humans improves glucose metabolism and beta cell function.
    Diabetologia. 2025;68:2754-2766.
    PubMed         Abstract available

  53. SCHREMS E, Gruber JR, Schiweck C, Ruf A, et al
    Daily life stress is linked to increased glucose levels in individuals with insulin resistance: a real-world assessment.
    Diabetologia. 2025;68:2709-2718.
    PubMed         Abstract available

  54. DUNCAN MS, Beach LB, Wolfe HL, Restar A, et al
    Sexual orientation, gender identity and cardiometabolic risk: a narrative review.
    Diabetologia. 2025;68:2652-2669.
    PubMed         Abstract available

  55. ANIAGYEI W, Sarfo-Kantanka O, Mohayideen S, Vivekanandan MM, et al
    Heterogeneity in clinically diagnosed type 1 diabetes: characterising a unique cohort with maintained C-peptide secretion in Ghana.
    Diabetologia. 2025 Nov 1. doi: 10.1007/s00125-025-06576.
    PubMed         Abstract available

  56. GITELMAN SE, Simmons K, Sherr JL, Leichter SB, et al
    Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes.
    Diabetologia. 2025 Nov 6. doi: 10.1007/s00125-025-06586.
    PubMed         Abstract available

  57. SCHULTZ ANO, Christensen R, Bollig G, Kidholm K, et al
    Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial.
    Diabetologia. 2025 Nov 7. doi: 10.1007/s00125-025-06585.
    PubMed         Abstract available

  58. DIMITROPOULOU NM, Beran M, Eussen SJPM, Dingena CF, et al
    Liver fat content is not elevated in people with type 1 diabetes: the Maastricht Study.
    Diabetologia. 2025 Nov 7. doi: 10.1007/s00125-025-06597.
    PubMed         Abstract available


    Invest Ophthalmol Vis Sci


  59. Retraction of: VEGF as a Survival Factor in Ex Vivo Models of Early Diabetic Retinopathy.
    Invest Ophthalmol Vis Sci. 2025;66:17.
    PubMed        

  60. NAM MH, Nahomi RB, Suk J, Panja S, et al
    DJ-1 Protects Human Retinal Endothelial Cells From Diabetes-Related Conditions and Prevents Ischemic Damage in Mouse Retinal Capillaries.
    Invest Ophthalmol Vis Sci. 2025;66:8.
    PubMed         Abstract available

  61. TAN R, Shahidzadeh A, Collazo A, Jiang X, et al
    The Association of Retinal Capillary Density and Retinal Thickness in Diabetic Retinopathy.
    Invest Ophthalmol Vis Sci. 2025;66:3.
    PubMed         Abstract available

  62. OMAE T, Ono S, Kamiya T, Otani S, et al
    Dipeptidyl Peptidase 4, a Novel Adipokine, Impairs Retinal Microcirculation in Patients With Type 2 Diabetes Mellitus.
    Invest Ophthalmol Vis Sci. 2025;66:4.
    PubMed         Abstract available


    J Biol Chem

  63. ZHANG S, Hu X, Zhang B, Liu J, et al
    Mapping cellular cytosolic pH in vivo under physiological and pathophysiological conditions.
    J Biol Chem. 2025;301:110637.
    PubMed         Abstract available


    J Clin Endocrinol Metab

  64. PRASAD TN, Pal R, Bhadada SK, Ram S, et al
    Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial.
    J Clin Endocrinol Metab. 2025 Nov 3:dgaf589. doi: 10.1210.
    PubMed         Abstract available

  65. DI CANDIA F, Rosanio FM, Franceschi R, Fierro A, et al
    Glucometabolic control and Anti-Transglutaminase Antibodies at Celiac Disease onset in Type 1 Diabetes youth.
    J Clin Endocrinol Metab. 2025 Nov 4:dgaf604. doi: 10.1210.
    PubMed         Abstract available


    J Clin Invest

  66. TAMBRALLI A, Knight JS
    Neutrophils take center stage in VEXAS syndrome pathogenesis.
    J Clin Invest. 2025;135:e199299.
    PubMed         Abstract available

  67. WONG CK, Drucker DJ
    Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.
    J Clin Invest. 2025;135:e194751.
    PubMed         Abstract available

  68. COOPER ME, van Raalte DH
    GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity.
    J Clin Invest. 2025;135:e194749.
    PubMed         Abstract available

  69. VALENCIA-RINCON E, Rai R, Chandra V, Wellberg EA, et al
    GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.
    J Clin Invest. 2025;135:e194743.
    PubMed         Abstract available


    J Diabetes Complications

  70. MORONEY E, Niewczas MA, Ekinci EI, MacIsaac RJ, et al
    Soluble tumor necrosis factor receptors (sTNFRs) as biomarkers for diabetic kidney disease: Soluble TNF receptors and DKD.
    J Diabetes Complications. 2025;40:109204.
    PubMed         Abstract available

  71. JORGENSEN IL, Thuesen ACB, Clausen TD, Ringholm L, et al
    Glycemia, management and outcomes of pregnant women with maturity-onset diabetes of the young - a single-center case series.
    J Diabetes Complications. 2025;40:109206.
    PubMed         Abstract available

  72. GUO J, Li Z, Carrillo-Larco RM, Hsia DS, et al
    Data-driven subtypes of newly diagnosed youth-onset type 2 diabetes in the USA.
    J Diabetes Complications. 2025;40:109207.
    PubMed         Abstract available

  73. ELHENAWY YI, Thabet RA, Hegazy MGA, El-Morsy SA, et al
    The role of oral alpha-lipoic acid as an adjuvant antioxidant therapy in diabetic nephropathy among children and adolescents with type 1 diabetes: a randomized controlled trial.
    J Diabetes Complications. 2025;40:109201.
    PubMed         Abstract available

  74. NISHIMURA M, Yonezawa K, Sawamura M, Tanaka T, et al
    Identification of biomarkers to predict renal function decline and its deceleration in patients with type 2 diabetes and diabetic kidney disease.
    J Diabetes Complications. 2025;40:109208.
    PubMed         Abstract available


    J Hypertens

  75. ROSTAMIAN S, Kaura A, Ariti C, Gupta A, et al
    The impact of blood pressure variability on cardiovascular and renal outcomes in patients with and without diabetes: insights from the Anglo-Scandinavian Cardiac Outcomes Trial.
    J Hypertens. 2025;43:2033-2041.
    PubMed         Abstract available

  76. PASDAR Z, Chandanani M, Dhillon N, Carter B, et al
    Hypertensive disorders of pregnancy increase the risk of future ophthalmic disorders: a systematic review and meta-analysis.
    J Hypertens. 2025;43:1903-1911.
    PubMed         Abstract available

  77. OKORO C, van der Kallen CJH, Mokhtar SBA, Zhou TL, et al
    Arterial stiffness is associated with small and large fiber neuropathy: The Maastricht Study.
    J Hypertens. 2025;43:1945-1952.
    PubMed         Abstract available


    JAMA

  78. PANT S
    FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes.
    JAMA. 2025 Nov 7. doi: 10.1001/jama.2025.19724.
    PubMed        


    Metabolism

  79. WANG Y, Sandforth A, von Schwartzenberg RJ, Ganslmeier M, et al
    Lifestyle intervention is more effective in high 1-hour post-load glucose than in prediabetes for restoring beta-cell function, reducing ectopic fat, and preventing type 2 diabetes.
    Metabolism. 2025 Nov 3:156430. doi: 10.1016/j.metabol.2025.156430.
    PubMed         Abstract available


    Ophthalmol Retina

  80. BUSZA AM, Duffy BV, Kakihara S, Fawzi AA, et al
    Foveal Avascular Zone Enlargement Significantly Improves Statistical Models for Detection of Diabetic Retinopathy Severity.
    Ophthalmol Retina. 2025 Nov 4:S2468-6530(25)00502.
    PubMed         Abstract available


    Pediatr Diabetes

  81. XU Z, Li X, Yuan X, Sun C, et al
    HLA-C? ( *) 0304 Associates With Beneficial Gut Microbiota and Later Onset of Type 1 Diabetes in Pediatric Cohorts.
    Pediatr Diabetes. 2025;2025:3013063.
    PubMed         Abstract available

  82. HEDAYATI S, Sotoudeh A, Mohabati F
    Caring Under Constraints: A Qualitative Study of Parental Needs in Pediatric Diabetes in Zabol.
    Pediatr Diabetes. 2025;2025:4306754.
    PubMed         Abstract available

  83. SONG H, Huang Y, Li J, Ding Y, et al
    Depressive Symptoms and Glycemic Control Among Children and Adolescents With Diabetes: The Mediation Effect of Self-Care Behaviors.
    Pediatr Diabetes. 2025;2025:8850165.
    PubMed         Abstract available


    PLoS One

  84. WANG L, Zhang R, Wang L, Wang Y, et al
    Single-cell sequencing reveals the response mechanisms of vascular endothelial cells to glucocorticoids in diabetic retinopathy.
    PLoS One. 2025;20:e0334230.
    PubMed         Abstract available

  85. DISOMA C, Malik A, Nisar A, Ullah I, et al
    Association of erythropoietin gene polymorphism (rs1617640 C>T/G) with diabetic retinopathy in Type 2 diabetes mellitus patients of Punjabi population in Pakistan.
    PLoS One. 2025;20:e0336014.
    PubMed         Abstract available

  86. NAKATANI E, Ohno H, Nagahama T, Tonoike T, et al
    Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes.
    PLoS One. 2025;20:e0336038.
    PubMed         Abstract available

  87. MAHMUD I, Saifullah MK, Morshed MN, Hossain MA, et al
    GCMS profiling of bioactive phytocompounds from Curculigo orchiodes Gaertn. root extract and evaluation of antioxidant, and antidiabetic activities: A computational drug development approach.
    PLoS One. 2025;20:e0335403.
    PubMed         Abstract available


  88. Correction: Counterintuitive relationship between the triglyceride glucose index and diabetic foot in diabetes patients: A cross-sectional study.
    PLoS One. 2025;20:e0336351.
    PubMed         Abstract available

  89. SHRESTHA N, Simkhada P, Kurmi O, Gautam S, et al
    Self-management of type 2 diabetes using a co-designed text based mobile health (mHealth) intervention in Nepal: A study protocol for randomised controlled trial.
    PLoS One. 2025;20:e0335333.
    PubMed         Abstract available

  90. ZHAO J, Liu X, Sun Q, He Y, et al
    Identification of Seven in absentia homolog 2 as a potential efferocytosis-related biomarker in diabetic foot ulcers.
    PLoS One. 2025;20:e0334163.
    PubMed         Abstract available

  91. KELLY R, Taggart L, Coates V, Truesdale M, et al
    Who presents the greatest challenge in intellectual disability research- participants or health and research professionals?
    PLoS One. 2025;20:e0332744.
    PubMed         Abstract available

  92. BHAGRA S, Ducharme-Smith AL, Juntunen MB, Liedl CP, et al
    Correction: Diabetes rescue, engagement, and management (D-REM) for hypoglycemia: Clinical trial protocol of a community paramedic program to improve diabetes management among adults with severe hypoglycemia.
    PLoS One. 2025;20:e0336047.
    PubMed         Abstract available


    Transplant Proc

  93. EGELI T, Unek T, Ozbilgin M, Agalar C, et al
    Evaluation of Etiology Based on Post-Transplant Pathological Diagnosis in Cases of Cryptogenic Cirrhosis.
    Transplant Proc. 2025 Sep 16:S0041-1345(25)00384.
    PubMed         Abstract available


    WMJ

  94. THIESSEN CF, Chlebeck P, Radke N, Tamburrini R, et al
    Total Pancreatectomy and Islet Autotransplantation for Chronic Pancreatitis Relieves Pain and Mitigates Diabetes Development.
    WMJ. 2025;124:326-332.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.